{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-028082","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.268456+00:00","generated_at":"2026-06-27T03:31:40.921603+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocular Therapeutix reports Q4 2021 DEXTENZA revenue $12.2M, up 77% YoY; net loss $3.9M","bullets":["DEXTENZA net product revenue $12.2M in Q4, +77% vs Q4 2020; full year $43.5M vs $17.4M.","Net loss $(3.9)M ($0.05 basic EPS) includes $15.9M non-cash gain; full year net loss $(6.6)M.","Cash $164.2M at Dec 31, 2021; expects to fund operations through 2023.","OTX-TKI (wet AMD) US Phase 1 fully enrolled; interim data expected H2 2022.","OTX-DED (dry eye) Phase 2 met primary endpoint; positive top-line data Dec 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-028082","json":"https://secwatch.observer/filing/0001104659-22-028082.json","markdown":"https://secwatch.observer/filing/0001104659-22-028082.md","text":"https://secwatch.observer/filing/0001104659-22-028082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/0001104659-22-028082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465922028082/tm227780d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:31:40.921603+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}